The Full Story
About
Our lead programme is focused on developing a transformative therapy for ovarian cancer. 1 in 52 women will be diagnosed with ovarian cancer in their lifetime, and currently only 35% of women diagnosed survive for 10 or more years. This is due to the highly immunosuppressive tumour environment, complex nature of the disease and few recent advances in the treatment landscape. Our team is developing an oncolytic viral therapy to selectively kill ovarian cancer cells, and cancer supporting cells - ‘CAFs’ - in addition to triggering the body’s immune system to detect and clear tumours.
Our lead programme is focused on developing a transformative therapy for ovarian cancer.
1 in 52 women will be diagnosed with ovarian cancer in their lifetime, and currently only 35% of women diagnosed survive for 10 or more years.
This is due to the highly immunosuppressive tumour environment, complex nature of the disease and few recent advances in the treatment landscape.
Patients with epithelial ovarian cancer almost invariably develop platinum resistant disease, for which the prognosis is very poor. Therapeutics in this setting have been challenging due to the prominence and complexity of the tumour microenvironment (TME) in ovarian cancer.
THEO-260 is a novel oncolytic immunotherapy specifically selected to target ovarian cancer and other stromal-rich tumours.
It is being investigated in trials evaluating two different routes of administration (IV and IP) in patients with platinum-resistant ovarian cancer
It has received regulatory approval for clinical trials in the UK, Spain, Canada, and the USA.
OCTOPOD-IV
THEO-260 is being evaluated in a Phase 1/2a clinical trial by intravenous delivery in ovarian cancer patients (OCTOPOD-IV).
Details of the OCTOPOD-IV trial can be found at https://clinicaltrials.gov/ under study identifier NCT06618235.
OCTOPOD-IP
THEO-260 is being evaluated in a Phase 1 clinical trial by intraperitoneal delivery in ovarian cancer patients (OCTOPOD-IP).
Details of the OCTOPOD-IP trial can be found at https://clinicaltrials.gov/ under study identifier NCT07211659.
